INS and metabolic disease: Furthermore, since the SGA blockade of M3R in pancreatic β-cells has been reported to reduce insulin release37, 38, 57, it would be important to use an M3R agonist to rescue the deficits of insulin secretion and/or other metabolic disorders caused by SGA blockade of M3R.